Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Alnylam Pharmaceuticals Stock Price (Quote) NASDAQ:ALNY
$127.77 ( 1.73% ) Friday, 27th May 2022
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $117.58 | $157.67 | Friday, 27th May 2022 ALNY stock ended at $127.77. This is 1.73% more than the trading day before Thursday, 26th May 2022. During the day the stock fluctuated 5.41% from a day low at $121.36 to a day high of $127.92. |
| 90 days | $117.58 | $180.14 | |
| 52 weeks | $117.58 | $212.00 |
Historical Alnylam Pharmaceuticals prices
| Date | Open | High | Low | Close | Volume |
| 2022-05-27 | $125.37 | $127.92 | $121.36 | $127.77 | 557 786 |
| 2022-05-26 | $127.19 | $129.06 | $125.02 | $125.60 | 330 291 |
| 2022-05-25 | $126.67 | $127.83 | $124.83 | $126.75 | 916 561 |
| 2022-05-24 | $128.59 | $128.59 | $124.80 | $127.05 | 536 433 |
| 2022-05-23 | $132.07 | $133.29 | $128.31 | $129.58 | 910 311 |
| 2022-05-20 | $129.82 | $133.13 | $129.22 | $132.27 | 1 168 848 |
| 2022-05-19 | $128.47 | $131.35 | $127.34 | $129.36 | 744 136 |
| 2022-05-18 | $126.44 | $130.90 | $125.52 | $128.31 | 660 860 |
| 2022-05-17 | $127.41 | $130.10 | $125.66 | $129.31 | 724 151 |
| 2022-05-16 | $125.74 | $127.91 | $123.27 | $124.87 | 939 591 |
| 2022-05-13 | $124.01 | $128.77 | $124.00 | $126.47 | 740 287 |
| 2022-05-12 | $119.30 | $123.14 | $117.58 | $121.33 | 1 054 714 |
| 2022-05-11 | $126.47 | $129.16 | $119.58 | $120.42 | 951 489 |
| 2022-05-10 | $126.21 | $131.06 | $124.34 | $128.18 | 1 022 182 |
| 2022-05-09 | $132.11 | $132.21 | $120.16 | $122.52 | 1 427 313 |
| 2022-05-06 | $135.16 | $136.50 | $132.13 | $134.75 | 602 064 |
| 2022-05-05 | $142.74 | $142.74 | $134.51 | $136.74 | 798 839 |
| 2022-05-04 | $143.72 | $144.98 | $138.73 | $143.43 | 948 745 |
| 2022-05-03 | $140.17 | $143.28 | $139.45 | $142.89 | 694 623 |
| 2022-05-02 | $131.59 | $139.15 | $131.59 | $139.05 | 850 561 |
| 2022-04-29 | $142.04 | $143.75 | $132.45 | $133.43 | 1 444 993 |
| 2022-04-28 | $150.36 | $151.31 | $138.52 | $143.16 | 1 913 613 |
| 2022-04-27 | $155.74 | $157.67 | $153.89 | $154.92 | 1 056 713 |
| 2022-04-26 | $160.15 | $161.11 | $154.58 | $155.00 | 986 582 |
| 2022-04-25 | $161.11 | $164.33 | $157.35 | $162.07 | 904 768 |
| 2022-04-22 | $168.34 | $169.00 | $166.43 | $167.04 | 250 271 |
| 2022-04-21 | $168.73 | $171.84 | $168.30 | $168.75 | 878 100 |
| 2022-04-20 | $164.28 | $168.32 | $160.48 | $167.95 | 528 200 |
| 2022-04-19 | $157.48 | $161.64 | $156.99 | $161.20 | 638 300 |
| 2022-04-18 | $166.16 | $166.74 | $155.85 | $156.68 | 654 800 |
| 2022-04-14 | $168.43 | $170.04 | $167.30 | $167.30 | 339 761 |
| 2022-04-13 | $160.79 | $168.59 | $158.81 | $168.59 | 485 026 |
| 2022-04-12 | $158.46 | $165.15 | $157.79 | $159.54 | 590 526 |
| 2022-04-11 | $163.80 | $165.27 | $157.18 | $157.30 | 475 420 |
| 2022-04-08 | $163.00 | $168.48 | $162.99 | $163.42 | 686 300 |
| 2022-04-07 | $157.95 | $168.04 | $157.66 | $162.25 | 1 047 500 |
| 2022-04-06 | $158.02 | $160.40 | $157.20 | $158.47 | 736 200 |
| 2022-04-05 | $161.25 | $165.98 | $159.47 | $159.91 | 661 400 |
| 2022-04-04 | $167.26 | $167.69 | $160.46 | $161.77 | 1 507 600 |
| 2022-04-01 | $166.41 | $180.14 | $164.01 | $169.28 | 1 711 827 |
| 2022-03-31 | $166.56 | $168.57 | $163.05 | $163.27 | 521 715 |
| 2022-03-30 | $167.41 | $169.87 | $165.02 | $165.25 | 394 466 |
| 2022-03-29 | $163.63 | $166.74 | $163.57 | $166.74 | 698 100 |
| 2022-03-28 | $163.46 | $164.13 | $158.85 | $161.65 | 664 700 |
| 2022-03-25 | $165.00 | $165.00 | $161.36 | $163.81 | 539 700 |
| 2022-03-24 | $164.26 | $164.26 | $160.59 | $163.70 | 865 300 |
| 2022-03-23 | $162.87 | $164.50 | $161.91 | $162.35 | 612 600 |
| 2022-03-22 | $163.57 | $164.14 | $161.22 | $163.83 | 693 223 |
| 2022-03-21 | $164.17 | $166.00 | $161.75 | $162.43 | 539 150 |
| 2022-03-18 | $164.73 | $166.43 | $163.45 | $165.25 | 1 032 444 |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The companys clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin amyloidosis (ATTR); ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; Fitusiran, an... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
